NLS Pharmaceutics Ltd. -CW25NLSPWPreferred / convertible
13F holders, Q1 2024 (March 31)6holders
$0.05avg. 13F price*
At the end of Q1 2024, 6 institutions reported holding NLS Pharmaceutics Ltd. -CW25 (NLSPW) in their 13F filings. The largest holders were Armistice Capital, LLC ($25K), Altium Capital Management LLC ($7K) and Hudson Bay Capital Management LP ($5K).
- Company
- NLS Pharmaceutics Ltd. -CW25
- CUSIP
- H57830111
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $612 |
| Exits | 0 | $0 |
Ownership 6 holders
| Armistice Capital, LLC | — | No change | 500,000 | $25K |
| Altium Capital Management LLC | — | No change | 200,000 | $7K |
| Hudson Bay Capital Management LP | — | No change | 100,000 | $5K |
| Susquehanna International Group, LLP | — | New | 12,548 | $612 |
| Clear Street LLC | — | Add +0.9% | 8,577 | $420 |
| UBS Group AG | — | Add +502.3% | 6,023 | $295 |
"% of holder's portfolio" is NLSPW's weight in each manager's 13F, not the share of NLS Pharmaceutics Ltd. -CW25 the manager owns.